Search - tctmd.com

Displaying 61 - 80 of 367

Sort: Relevancy | Date

TARGET BP 1: Alcohol-Based RDN Promises Single Treatment for Resistant BP

News Conference News ACC 2024

TARGET BP 1: Alcohol-Based RDN Promises Single Treatment for Resistant BP

April 16, 2024

KARDIA-2: Zilebesiran Drops BP on Top of Common Antihypertensives

News Conference News ACC 2024

KARDIA-2: Zilebesiran Drops BP on Top of Common Antihypertensives

April 11, 2024

Effect of Alcohol-mediated Renal Denervation on Blood Pressure in the Presence of Antihypertensive Drugs: 3-month Primary Results From the Target BP I Randomized Trial

Presentation ACC 2024

Effect of Alcohol-mediated Renal Denervation on Blood Pressure in the Presence of Antihypertensive Drugs: 3-month Primary Results From the Target BP I Randomized Trial

Presenter: David E. Kandzari

April 08, 2024

Antihypertensives Linked to Lower Long-term Dementia Risk

News Daily News

Antihypertensives Linked to Lower Long-term Dementia Risk

April 01, 2024

Evoque and Patisiran: A Tale of Two Regulatory Journeys

News Opinion Off Script

Evoque and Patisiran: A Tale of Two Regulatory Journeys

Sanjay Kaul, MD

March 29, 2024

Icosapent Ethyl Lowers CV Risk Across Lp(a) Range: REDUCE-IT

News Conference News ACC 2024

Icosapent Ethyl Lowers CV Risk Across Lp(a) Range: REDUCE-IT

March 27, 2024

FDA Approves Aprocitentan for Inadequately Controlled Hypertension

News Daily News

FDA Approves Aprocitentan for Inadequately Controlled Hypertension

Michael O'Riordan

March 20, 2024

Patients With CKD Remain Underrepresented in Trials of CV Meds

News Daily News

Patients With CKD Remain Underrepresented in Trials of CV Meds

March 08, 2024

Salt Substitute Slashes New Hypertension Diagnoses: DECIDE-Salt

News Daily News

Salt Substitute Slashes New Hypertension Diagnoses: DECIDE-Salt

February 14, 2024

BP Reductions Last 5 Years After Bariatric Surgery: GATEWAY

News Daily News

BP Reductions Last 5 Years After Bariatric Surgery: GATEWAY

Michael O'Riordan

February 07, 2024

Universal Risk Tool Works Well in Both Primary and Secondary Prevention

News Daily News

Universal Risk Tool Works Well in Both Primary and Secondary Prevention

Michael O'Riordan

February 01, 2024

AHA Selects 2023’s Leading Cardiovascular Research

News Daily News

AHA Selects 2023’s Leading Cardiovascular Research

December 22, 2023

Stopping Tirzepatide Leads to Rebound in Weight, Cardiometabolic Risk

News Daily News

Stopping Tirzepatide Leads to Rebound in Weight, Cardiometabolic Risk

December 12, 2023

Rethink Race in Pooled Cohort Equations for ASCVD, REGARDS Data Suggest

News Daily News

Rethink Race in Pooled Cohort Equations for ASCVD, REGARDS Data Suggest

December 11, 2023

Long-term ALLHAT Data Affirm Parity of Antihypertensive Meds

News Daily News

Long-term ALLHAT Data Affirm Parity of Antihypertensive Meds

December 06, 2023

POP-HT: Physician-Guided Self-Monitoring Improves BP After Hypertensive Pregnancy

News Conference News AHA 2023

POP-HT: Physician-Guided Self-Monitoring Improves BP After Hypertensive Pregnancy

November 13, 2023

Slash Dietary Sodium, Slash Blood Pressure: CARDIA-SSBP

News Conference News AHA 2023

Slash Dietary Sodium, Slash Blood Pressure: CARDIA-SSBP

Michael O'Riordan

November 12, 2023

RNA-Interference Agent Zilebesiran Looks Promising for BP-Lowering KARDIA-1

News Conference News AHA 2023

RNA-Interference Agent Zilebesiran Looks Promising for BP: KARDIA-1

November 11, 2023

FDA Approves Paradise Renal Denervation System: What Comes Next?

News Daily News

FDA Approves Paradise Renal Denervation System: What Comes Next?

November 08, 2023

RADIANCE Modest Renal Denervation Effect Remains at 6 Months

News Conference News TCT 2023

RADIANCE: 'Modest' Renal Denervation Effect Remains at 6 Months

October 31, 2023

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.